

Cover Story
Guest Editorial
At a recent NIH study section that I chaired, we had many applications that we reviewed as a group before the meeting. At the meeting, we were required to discuss over 50% of the grants.
By Claire Dietz and Matthew Bin Han Ong
Conversation with The Cancer Letter
By Matthew Bin Han Ong and Claire Dietz
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
NCI Trials


NCI Trials for July
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds
- CBER Director Vinay Prasad dared to “say no to drugs”
- At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.” - Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
















